SCHEDULE: State Street Discloses 6.4% Stake in Myriad Genetics

State Street Corporation has reported a 6.4% beneficial ownership stake in Myriad Genetics Inc. common stock as of December 31, 2025.

Summary

• State Street Corporation filed a Schedule 13G, indicating its beneficial ownership in Myriad Genetics Inc.
• The reporting person, State Street Corporation, beneficially owns 5,966,567 shares of Myriad Genetics Inc. common stock.
• This ownership represents 6.4% of the total class of Myriad Genetics Inc. common stock.
• State Street Corporation holds shared voting power over 5,683,556 shares.
• State Street Corporation holds shared dispositive power over 5,966,567 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure, as it indicates a significant, passive institutional investment in Myriad Genetics by State Street Corporation, a major asset manager.

Positives

• A major institutional investor, State Street Corporation, holds a significant 6.4% stake in Myriad Genetics Inc., which can be interpreted as a vote of confidence.

Future Outlook

NA

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G are common for large asset managers like State Street Corporation, reflecting their role in managing diversified portfolios across various sectors, including healthcare and biotechnology. Myriad Genetics operates in the genetic testing and precision medicine space, an area of significant interest for institutional investors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by State Street Corporation may provide a degree of confidence or stability regarding the company's ownership structure.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of State Street Corporation's passive ownership stake in Myriad Genetics. While the presence of a major institutional investor can be a positive signal, the filing itself does not contain financial performance data, strategic updates, or forward-looking guidance from Myriad Genetics that would warrant a stronger recommendation. Therefore, a 'hold' recommendation is appropriate for existing investors, pending further fundamental analysis of Myriad Genetics' operational and financial performance.

Keywords

Myriad Genetics, State Street Corporation, Schedule 13G, Common Stock, Institutional Ownership, Beneficial Ownership, Healthcare, Biotechnology, Diagnostics